“Revolutionizing Medicine: How Artificial Intelligence is Changing the Game in the Development of Antibodies and Drugs”

2023-05-06 17:25:00

Artificial intelligence and the consequences of its use have been criticized on a wide variety of fronts, but there are sectors that would benefit

Artificial intelligence, so criticized for some of its negative consequences, might generate a before and following in medicine by having the possibility of developing antibodies that make it possible to combat diseases such as COVID-19 more effectively.

At least this is the proposal of a group of researchers from the University of Stanford and Oxford, who recently published an article in the journal Nature Biotechnology.

According to the first advances, artificial intelligence might be useful for the development of antibodies and drugs that help improve the response of the immune system.

“There is a lot of interest in figuring out how to engineer antibodies,” says Stanford University biochemist Dr. Peter Kimco-author of the research.

The research focuses on the development of neural networks with which protein language models can work, similar to the language models used by applications such as ChatGPT, only that instead of being fed with texts and information, protein sequences will be introduced. .

Using AI technology, researchers can speed up the processing of models that would not only generate proteins with a precise structure to do their job, but might even generate new ones that accommodate disease mutations. With this, it would be possible to fight once morest mutations of diseases such as COVID-19 and, in this way, have more effective vaccines.

AI might be beneficial in medical research and development

This first model studied in the research was fed with 100 million protein sequences, although it was only put into practice with a few thousand, which has already shown an improvement in the antibody response once morest SARS-CoV.2, Ebola and the flu.

The information processing capacity of AI would allow, for example, to cover areas that are currently unreachable for biotechnological engineers, such as the improvement of G protein receptors, a family of proteins located in cell membranes related to disorders neurological.

Although this type of research is still in progress, companies such as Absci have already taken the first steps to manufacture antibody drugs that treat diseases such as breast cancer, indicated Sputnik Mundo.

“This is a tool that people will use to improve their antibodies. I think this is fantastic,” he said. Charlotte Deaneimmunoinformatics researcher at the University of Oxford

1683405456
#favor #artificial #intelligence #medicine

Leave a Replay